KLCM
GSK icon

KG&L Capital Management’s GSK GSK Stock Holding History

KG&L Capital Management’s Portfolio GSK Stock Details GSK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$258K Sell
4,850
-7,723
-61% -$419K 0.18% 108
2025
Q4 		$610K Sell
12,573
-170
-1% -$7.93K 0.15% 122
2025
Q3 		$546K Sell
12,743
-1,265
-9% -$49.4K 0.15% 121
2025
Q2 		$536K Buy
14,008
+1,353
+11% +$51.7K 0.16% 111
2025
Q1 		$488K Sell
12,655
-376
-3% -$13.8K 0.16% 124
2024
Q4 		$441K Sell
13,031
-3,654
-22% -$132K 0.14% 129
2024
Q3 		$679K Buy
16,685
+5,104
+44% +$209K 0.22% 98
2024
Q2 		$444K Sell
11,581
-33,002
-74% -$1.39M 0.15% 131
2024
Q1 		$1.91M Sell
44,583
-3,662
-8% -$151K 0.76% 29
2023
Q4 		$1.79M Sell
48,245
-1,106
-2% -$39.7K 0.75% 28
2023
Q3 		$1.79M Sell
49,351
-759
-2% -$26.9K 0.86% 25
2023
Q2 		$1.79M Sell
50,110
-190
-0.4% -$6.82K 0.86% 24
2023
Q1 		$1.79M Buy
50,300
+1,636
+3% +$57.2K 0.94% 24
2022
Q4 		$1.71M Buy
+48,664
New +$1.62M 0.99% 23
2022
Q3 		– Sell
-23,767
Closed -$1.29M – 131
2022
Q2 		$1.29M Buy
23,767
+78
+0.3% +$4.31K 0.7% 35
2022
Q1 		$1.29M Buy
23,689
+180
+0.8% +$9.78K 0.54% 49
2021
Q4 		$1.3M Sell
23,509
-634
-3% -$33K 0.52% 56
2021
Q3 		$1.15M Sell
24,143
-3,394
-12% -$170K 0.51% 55
2021
Q2 		$1.37M Buy
27,537
+1,095
+4% +$52.6K 0.62% 41
2021
Q1 		$1.18M Buy
26,442
+7,476
+39% +$339K 0.59% 42
2020
Q4 		$872K Buy
18,966
+1,524
+9% +$70K 0.48% 51
2020
Q3 		$820K Buy
17,442
+5,834
+50% +$292K 0.51% 48
2020
Q2 		$591K Buy
11,608
+450
+4% +$23.1K 0.45% 53
2020
Q1 		$528K Buy
11,158
+5,496
+97% +$293K 0.53% 51
2019
Q4 		$332K Buy
5,662
+504
+10% +$28K 0.28% 72
2019
Q3 		$275K Buy
5,158
+1,004
+24% +$51.6K 0.25% 76
2019
Q2 		$207K Buy
+4,154
New +$208K 0.2% 85

Other funds holding GSK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
JEST
JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

KG&L Capital Management's GSK Position: Q1 2026 in Review

KG&L Capital Management reduced its GSK (GSK) stake by 61% in Q1 2026, selling an estimated $419K and leaving 4,850 shares worth $258K. The position accounts for 0.18% of the portfolio, ranked #108.

KG&L Capital Management first reported a position in GSK in Q2 2019 and has held it in 27 quarters since. The position peaked at $1.91M in Q1 2024. 1,031 funds tracked by Wall St. Rank hold GSK as of Q1 2026.

  • KG&L Capital Management held 4,850 shares of GSK worth $258K as of Q1 2026.
  • KG&L Capital Management sold 7,723 GSK shares in Q1 2026, an estimated $419K.
  • GSK made up 0.18% of KG&L Capital Management's portfolio in Q1 2026, its #108 holding.
  • KG&L Capital Management first reported a position in GSK in Q2 2019 and has held it in 27 quarters since.
  • KG&L Capital Management's GSK position peaked at $1.91M in Q1 2024.
  • 1,031 funds tracked by Wall St. Rank held GSK as of Q1 2026.

Based on KG&L Capital Management's 13F filing for Q1 2026, filed 23 Apr 2026.